A Circulating miRNA Signature for Stratification of Breast Lesions among Women with Abnormal Screening Mammograms.

Autor: Loke SY; Cellular and Molecular Research, Humphrey Oei Institute of Cancer Research, National Cancer Centre, Singapore 169610, Singapore.; SingHealth Duke-NUS Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857, Singapore., Munusamy P; Cellular and Molecular Research, Humphrey Oei Institute of Cancer Research, National Cancer Centre, Singapore 169610, Singapore., Koh GL; Cellular and Molecular Research, Humphrey Oei Institute of Cancer Research, National Cancer Centre, Singapore 169610, Singapore., Chan CHT; Cellular and Molecular Research, Humphrey Oei Institute of Cancer Research, National Cancer Centre, Singapore 169610, Singapore., Madhukumar P; SingHealth Duke-NUS Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857, Singapore.; Division of Surgical Oncology, National Cancer Centre, Singapore 169610, Singapore.; Department of General Surgery, Singapore General Hospital, Singapore 169608, Singapore., Thung JL; Division of Surgical Oncology, National Cancer Centre, Singapore 169610, Singapore.; SingHealth Duke-NUS Breast Centre, Singapore 169610, Singapore., Tan KTB; SingHealth Duke-NUS Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857, Singapore.; Division of Surgical Oncology, National Cancer Centre, Singapore 169610, Singapore.; Department of General Surgery, Singapore General Hospital, Singapore 169608, Singapore.; SingHealth Duke-NUS Breast Centre, Singapore 169610, Singapore.; Department of General Surgery, Sengkang General Hospital, Singapore 544886, Singapore., Ong KW; Division of Surgical Oncology, National Cancer Centre, Singapore 169610, Singapore.; SingHealth Duke-NUS Breast Centre, Singapore 169610, Singapore., Yong WS; SingHealth Duke-NUS Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857, Singapore.; Division of Surgical Oncology, National Cancer Centre, Singapore 169610, Singapore.; Department of General Surgery, Singapore General Hospital, Singapore 169608, Singapore.; SingHealth Duke-NUS Breast Centre, Singapore 169610, Singapore., Sim Y; SingHealth Duke-NUS Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857, Singapore.; Division of Surgical Oncology, National Cancer Centre, Singapore 169610, Singapore.; SingHealth Duke-NUS Breast Centre, Singapore 169610, Singapore., Oey CL; Division of Surgical Oncology, National Cancer Centre, Singapore 169610, Singapore.; SingHealth Duke-NUS Breast Centre, Singapore 169610, Singapore., Lim SZ; SingHealth Duke-NUS Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857, Singapore.; Division of Surgical Oncology, National Cancer Centre, Singapore 169610, Singapore.; Department of General Surgery, Singapore General Hospital, Singapore 169608, Singapore.; SingHealth Duke-NUS Breast Centre, Singapore 169610, Singapore., Chan MYP; Department of General Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore., Ho TSJ; SingHealth Duke-NUS Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857, Singapore.; Division of Oncologic Imaging, National Cancer Centre, Singapore 169610, Singapore., Khoo BKJ; SingHealth Duke-NUS Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857, Singapore.; Division of Oncologic Imaging, National Cancer Centre, Singapore 169610, Singapore., Wong SLJ; Division of Oncologic Imaging, National Cancer Centre, Singapore 169610, Singapore., Thng CH; SingHealth Duke-NUS Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857, Singapore.; Division of Oncologic Imaging, National Cancer Centre, Singapore 169610, Singapore., Chong BK; Department of Diagnostic Radiology, Tan Tock Seng Hospital, Singapore 308433, Singapore., Tan EY; Department of General Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore., Tan VK; SingHealth Duke-NUS Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857, Singapore.; Division of Surgical Oncology, National Cancer Centre, Singapore 169610, Singapore.; Department of General Surgery, Singapore General Hospital, Singapore 169608, Singapore.; SingHealth Duke-NUS Breast Centre, Singapore 169610, Singapore., Lee ASG; Cellular and Molecular Research, Humphrey Oei Institute of Cancer Research, National Cancer Centre, Singapore 169610, Singapore.; SingHealth Duke-NUS Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857, Singapore.; Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117593, Singapore.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2019 Nov 26; Vol. 11 (12). Date of Electronic Publication: 2019 Nov 26.
DOI: 10.3390/cancers11121872
Abstrakt: Although mammography is the gold standard for breast cancer screening, the high rates of false-positive mammograms remain a concern. Thus, there is an unmet clinical need for a non-invasive and reliable test to differentiate between malignant and benign breast lesions in order to avoid subjecting patients with abnormal mammograms to unnecessary follow-up diagnostic procedures. Serum samples from 116 malignant breast lesions and 64 benign breast lesions were comprehensively profiled for 2,083 microRNAs (miRNAs) using next-generation sequencing. Of the 180 samples profiled, three outliers were removed based on the principal component analysis (PCA), and the remaining samples were divided into training ( n = 125) and test ( n = 52) sets at a 70:30 ratio for further analysis. In the training set, significantly differentially expressed miRNAs (adjusted p < 0.01) were identified after correcting for multiple testing using a false discovery rate. Subsequently, a predictive classification model using an eight-miRNA signature and a Bayesian logistic regression algorithm was developed. Based on the receiver operating characteristic (ROC) curve analysis in the test set, the model could achieve an area under the curve (AUC) of 0.9542. Together, this study demonstrates the potential use of circulating miRNAs as an adjunct test to stratify breast lesions in patients with abnormal screening mammograms.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje